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Identity 
Other names: CREBBP (CREB binding protein 
(Rubinstein-Taybi syndrome)); RTS (Rubinstein-
Taybi syndrome); RSTS 
HGNC (Hugo): CREBBP 
Location: 16p13.3 
 




The gene spans about 190 kb; transcription from 
centromere to telomere. 
Transcription 
8.7 kb mRNA, with a 7.3 kb coding sequence. 
Protein 
Description 
2442 amino acids; 265 kDa; from NH2-term, is made  
of a CREB-Binding domain, a bromodomain. 
Cystidine/Histidine-rich domains, and Glutamine-rich 
domains in COOH-term. 
Expression 





Binds specifically to the DNA-binding protein CREB 
and connects it to the basal transcriptional machinery: 
transcription coactivator, with P300; has histone 
acetyltransferase activity; essential role in 
embryogenesis, cell differentiation, apoptosis, and 
proliferation; involved in the regulation of cell cycle 




t(8;16)(p11;p13)/M4 ANLL --> MOZ/CBP 
Disease 
Acute non lymphocytic leukemia (ANLL) and 
treatment related ANLL (t-ANLL). 
Prognosis 
Poor: remission is obtained in half cases; survival s 
often less than 1 year. 
Cytogenetics 
+8 as an additional anomalies in half cases. 
Hybrid/Mutated gene 
5' MOZ - 3' CBP. 
 
 










N-term finger motifs and acetyl transferase from MOZ 
fused to most of CBP, with a breakpoint in 5' of the 
CREB binding domain of CBP. 
t(11;16)(q23;p13)/t-ANLL --> MLL/CBP 
Disease 
Treatment related ANLL (t-ANLL); should be very 
close to the t(11;22)(q23;q13). 
Prognosis 
Likely to be poor. 
Hybrid/Mutated gene 
5' MLL - 3' CBP. 
Abnormal protein 
N-term AT hook and DNA methyltransferase from 
MLL fused to most of CBP; variable breakpoint in 
CBP: either in 5' of the CREB binding domain (like in 
the t(8;16)), or just upstream of the bromodomain. 
Rubinstein-taybi syndrome 
Note 
Due to CBP haploinsufficiency. 
Disease 
Autosomal dominant disorder with mental retardation, 
facial dysmorphia, broad thumbs/halluces, cardiac 
anomalies, and an increased risk of medulloblastoma, 
meningioma, and neuroblastoma. 
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